##plugins.themes.bootstrap3.article.main##

Mitochondria are referred to as the energy centers of cells, and mitochondrial DNA are known to alter the mitochondrial respiratory chain, which reduces cellular energy and causes ion-channel malfunction and neuronal cell death. As majority of the cells contain mitochondria, these disorders involve multiple systems. Since the energy requirements of different tissues vary, their vulnerability to mitochondrial dysfunction also varies in terms of threshold. This causes these disorders to appear clinically in a variety of ways and with significant phenotypic overlap. The genotypic and phenotypic definitions of some specific symptoms are, nevertheless, well established. Potentially deadly mitochondrial toxins are present in some epileptic medications and early diagnosis of the condition can help prevent serious morbidities. We describe a typical case of sodium valproate and lamotrigine-induced fast multiaxial worsening in a patient with myoclonic epilepsy with red ragged fibers (MERRF) as these drugs act as mitochondrial poisons and could prove life threatening for patients with mitochondrial diseases. When mitochondrial cocktail was introduced and the problematic medicines were removed, the symptoms were somewhat reversed. MERRF in progeny of non- consanguineous parents is a rare occurrence resulting in poor prognosis of the disease. Epileptic drugs lamotrigine and sodium valproate should be avoided as these drugs worsen myoclonus and cause mitochondrial toxicities. With knowledge of the information in this scenario, further harm to the patient can be prevented.

References

  1. Genton P, Striano P, Minassian BA. The history of progressive myoclonus epilepsies. Epileptic Disord. 2016; 18(S2): 3-10.
     Google Scholar
  2. Satishchandra P, Sinha S. Progressive myoclonic epilepsy. Neurol India. 2010; 58(4): 514-22.
     Google Scholar
  3. Classification of progressive myoclonus epilepsies and related disorders. Marseille Consensus Group. Ann Neurol. 1990; 28(1): 113-6.
     Google Scholar
  4. Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. The Lancet Neurol. 2005; 4(4): 239-248.
     Google Scholar
  5. Crespel A, Ferlazzo E, Franceschetti S, Genton P,Gouider R, Kälviäinen R et al. Unverricht-Lundborg disease. Epileptic Disord. 2016; 18(S2): 28-37.
     Google Scholar
  6. Turnbull J, Tiberia E, Striano P, Genton P, Carpenter S, Ackerley CA, et al. Laforadisease. Epileptic Disord. 2016; 18(S2): 38-62.
     Google Scholar
  7. Nita DA, Mole SE, Minassian BA. Neuronal ceroidlipofuscinoses. Epileptic Disord. 2016; 18(S2): 73-88.
     Google Scholar
  8. Dibbens L, Schwake M, Saftig P, Rubboli G. SCARB2/LIMP2 deficiency in action myoclonus-renal failure syndrome. Epileptic Disord. 2016; 18(S2): 63-72.
     Google Scholar
  9. Franceschetti S, Sialidoses CL. Epileptic Disord. 2016; 18(S2): 89-93.
     Google Scholar
  10. Kasai J, Onuma T, Kato M, Kato T, Takeya J, Sekimoto M, et al. Differences in evoked potential characteristics between DRPLA patients and patients with progressive myoclonic epilepsy: preliminary findings indicating usefulness for differential diagnosis. Epilepsy Res 1999; 37: 3-11.
     Google Scholar
  11. Lamperti C, Zeviani M. Myoclonus epilepsy in mitochondrial disorders. Epileptic Disord. 2016; 18(S2): 94-102.
     Google Scholar
  12. Baillie TA. Metabolism of valproate to hepatotoxic intermediates. Pharm Weekblad Scientific Edition. 1992; 14: 122-125.
     Google Scholar
  13. McKenna MC. The glutamate-glutamine cycle is not stoichiometric: Fates of glutamate in brain. J Neurosci Res. 2007; 85: 3347-3358.
     Google Scholar
  14. Rahman S. Mitochondrial disease and epilepsy. Dev Med Child Neurol. 2012; 54: 397-406.
     Google Scholar


Most read articles by the same author(s)